04.15.25 -- Applying AI To Identify Synergistic Drug Combinations For Cancer Treatment

Dive into the world of ophthalmic drug development, where careful considerations in the preclinical phase must be taken to facilitate advancement into first-in-human clinical trials.

Building more sustainable practices across the pharmaceutical industry takes a collaborative and transparent effort. One leading CDMO is leveraging its solvent recovery efforts to yield major strides.

Discover how PBPK models combined with in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development.

Unlock novel E3 ligase ligands and revolutionize your protein degrader design. Learn how innovative MST assays can expand your understanding and accelerate your research on undruggable targets.

Emerging biotechs are behind many of the pharma industry’s latest therapeutic innovations. And while CDMOs are eager to work with them, they must learn to accommodate their unique needs.